Tau Protein
Tau is well established as a microtubule-associated protein in neurons. They have roles primarily in maintaining the stability of microtubules in axons and are abundant in the neurons of the central nervous system (CNS). However, under pathological conditions, aberrant assembly of tau into insoluble aggregates is accompanied by synaptic dysfunction and neural cell death in a range of neurodegenerative disorders, collectively referred to as tauopathies.
All Product Categories
-
Tau Protein Related Products (216)
Related Products (216)
-
Antibodies (5)
-
Tau Peptide (244-274) (Repeat 1 Domain)
0 ImagesCat. No.: HY-P4924CAS No.: 330456-24-1Tau Peptide (244-274) (Repeat 1 Domain) is aTau fragment.
-
Etalanetug (Mouse IgG2a)
0 ImagesCat. No.: HY-P990995ACAS No.: 2690265-18-8Synonyms: 7G6 Antibody; 7G6-IgG2aEtalanetug (Mouse IgG2a) (7G6 Antibody) is a mouse monoclonal antibody targeting the HVPGG motif in the microtubule-binding domain of tau protein. Etalanetug (Mouse IgG2a) reduces the levels of insoluble tau protein in multiple brain regions and inhibits the seeding and spread of pathological tau protein. Etalanetug (Mouse IgG2a) is applicable to research related to Alzheimer's disease.
-
TTBK1-IN-4
0 ImagesCat. No.: HY-157307CAS No.: 2735015-54-8TTBK1-IN-4 (Compound 19) is a potent inhibitor of TTBK1, with a biochemical IC₅₀ of 2.3 nM and a cellular IC₅₀ of 42 nM. TTBK1-IN-4 can be used for research on Alzheimer's disease.
-
D-TLKIVWC
0 ImagesCat. No.: HY-P11593CAS No.: 3105302-84-6D-TLKIVWC is a tau fibril disaggregator. D-TLKIVWC has low immunogenicity and anti-degradation properties. D-TLKIVWC disrupts intermolecular hydrogen bonds of tau via a stress-release mechanism. D-TLKIVWC can be used in the research of amyloid diseases such as Alzheimer's disease.
-
Aβ/tau aggregation-IN-4
0 ImagesCat. No.: HY-180843CAS No.: 3105860-83-8Aβ/tau aggregation-IN-4 (Compound D21) is an Aβ/tau aggregation inhibitor. Aβ/tau aggregation-IN-4 promotes the degradation of Aβ40/42 (Aβ40, IC50 = 2.151 μM; Aβ42, IC50 = 3.622 μM). Aβ/tau aggregation-IN-4 shows selective AChE inhibition (IC50: 5.56 μM). Aβ/tau aggregation-IN-4 inhibits MAO-A and MAO-B with IC50s of 0.59 μM and 0.09 μM, respectively. Aβ/tau aggregation-IN-4 suppresses intracellular ROS levels. Aβ/tau aggregation-IN-4 can be used in the research of Alzheimer's disease.
-
Tau Peptide (245-274) (Repeat 1 Domain)
0 ImagesCat. No.: HY-P4927CAS No.: 1428134-39-7Tau Peptide (245-274) (Repeat 1 Domain) is aTau fragment.
-
(Rac)-Lonafarnib
0 ImagesCat. No.: HY-15136BCAS No.: 193275-86-4Synonyms: Sch66336 racemate(Rac)-Lonafarnib (Sch66336 racemate) is an isomer of Lonafarnib (HY-15136). Lonafarnib (Sch66336) is an orally active, blood-brain barrier penetrant farnesyltransferase (FPTase) inhibitor. Lonafarnib increases the phosphorylation levels of Akt, CaMKII and CREB, upregulates BDNF expression in the hippocampus, elevates the content of α7nAChR on cell membranes, and blocks the isoprenylation of H-Ras. Lonafarnib repairs synapses and reverses spatial memory deficits in Aβ1-42 model mice. Lonafarnib inhibits RSV fusion and replication, and alleviates virus-induced lung injury. Lonafarnib activates the lysosomal and autophagic pathways, and reduces the phosphorylation and aggregation of tau. Lonafarnib acts synergistically with Sorafenib (HY-10201) to promote apoptosis, and inhibits the proliferation and invasion of melanoma cells. Lonafarnib inhibits the farnesylation of progerin, repairs nuclear membrane defects, and activates the cGAS-STING-STAT1 signaling pathway. Lonafarnib can be used in research related to diseases including Alzheimer's disease, viral infections, melanoma, and progeria.
-
Tau Peptide (294-305) (human)
0 ImagesCat. No.: HY-P4960CAS No.: 1428135-29-8Tau Peptide (294-305) (human) is aTau fragment.
-
AChE/BChE-IN-29
0 ImagesCat. No.: HY-175658AChE/BChE-IN-29 is an AChE/BChE inhibitor. AChE/BChE-IN-29 exhibits balanced dual cholinesterase inhibitory activity with IC50 values of 2.1 μM for Electrophorus electricus AChE (eeAChE) and 6.3 μM for equine serum butyrylcholinesterase (eqBChE). AChE/BChE-IN-29 effectively inhibits amyloid-β (Aβ42) aggregation and tau protein aggregation in E. coli cell models. AChE/BChE-IN-29 can be used for the study of Alzheimer’s disease (AD).
-
Tau Peptide (45-73) (Exon 2/Insert 1 Domain)
0 ImagesCat. No.: HY-P4972CAS No.: 2022956-54-1Tau Peptide (45-73) (Exon 2/Insert 1 Domain) is aTau fragment.
-
17β-HSD10/CDK5-IN-1
0 ImagesCat. No.: HY-18328017β-HSD10/CDK5-IN-1 is a poent dual 17β-HSD10 and CDK5 inhibitor with IC50s of 2.44 and 0.26 μM for 17β-HSD10 and CDK5, respectively. 17β-HSD10/CDK5-IN-1 reduces ROS accumulation, attenuates pathological Tau phosphorylation, reduces Aβ plaque deposition, and ameliorates cognitive deficits in Alzheimer's mice. 17β-HSD10/CDK5-IN-1 can be used for the research of Alzheimer's disease.
-
17β-HSD10-IN-4
0 ImagesCat. No.: HY-18202817β-HSD10-IN-4 is a selective brain-penetrant 17β-HSD10 inhibitor with an IC50 of 6.33 μM. 17β-HSD10-IN-4 forms key interactions with the 17β-HSD10 catalytic triad to functionally inhibit the enzyme, without altering its protein levels. 17β-HSD10-IN-4 restores mitochondrial function, reduces ROS levels, increases ATP production, and suppresses cytochrome c release. 17β-HSD10-IN-4 attenuates CDK5/p25 activation, reduces Tau hyperphosphorylation, Aβ plaque load and restores brain-derived neurotrophic factor levels. 17β-HSD10-IN-4 improves cognitive function.17β-HSD10-IN-4 can be used for the research of Alzheimer's disease.
-
MPT0G413
0 ImagesCat. No.: HY-141541CAS No.: 2241643-23-0MPT0G413 (Compound 6) is a potent, selective, orally active and brain-penetrant HDAC6 inhibitor with an IC50 of 3.92 nM. MPT0G413 decreases not only the level of phosphorylation of tau proteins but also the aggregation of tau proteins. MPT0G413 can ameliorate the impaired learning and memory. MPT0G413 can be used for the research of neurological disease, such as Alzheimer's disease.
-
Edutirsen sodium scrambled negative control
0 ImagesCat. No.: HY-177628BEdutirsen sodium scrambled negative control is the sequence scrambled negative control of Edutirsen sodium.
-
Surfen
0 ImagesSurfen is a potent heparan sulfate antagonist. Surfen inhibits FGF2 binding and signal transduction. Surfen binds to glycosaminoglycans and reduces tau hyperphosphorylation. Surfen inhibits the activity of recombinant uronyl 2-O-sulfotransferase with an IC50 of approximately 2 μM. Surfen inhibits HSV-1 viral infection. Surfen inhibits neural differentiation, delays remyelination, and alleviates EAE.
-
BChE-IN-41
0 ImagesCat. No.: HY-174381BChE-IN-41 is a highly selective Butyrylcholinesterase (BChE) inhibitor (IC50 =12 nM, Ki = 6.6 nM). BChE-IN-41 has high brain penetration with a brain-to-plasma ratio of 9.0. BChE-IN-41 has pro-cognitive effects on mice with AD-like symptoms induced by Scopolamine (HY-N0296) and Aβ1-42.
-
TTBK2 Recombinant Human Active Protein Kinase
0 ImagesCat. No.: HY-E70871TTBK2 is a tau tubulin kinase. Mutations in TTBK2 cause spinocerebellar ataxia type 11, a disorder exhibiting both loss of Purkinje cells and widespread deposition of tau. TTBK2 Recombinant Human Active Protein Kinase is a recombinant TTBK2 protein that can be used to study TTBK2-related functions.
-
ARN25699
0 ImagesCat. No.: HY-183584ARN25699 is a kinase inhibitor with an IC50 of 5.5 nM against GSK-3β, 2.2 nM against FYN-α, and 242.3 nM against DYRK1A, and it exhibits oral bioavailability. ARN25699 reduces hyperphosphorylation of tau protein and promotes microtubule bundle formation. ARN25699 has a broader kinome inhibitory profile and targets kinases associated with the pathogenic mechanisms linked to Alzheimer's disease. ARN25699 can be used in the research of Alzheimer's disease and related tauopathies.
-
BIIB076
0 ImagesCat. No.: HY-P991376BIIB076 is a human monoclonal antibody (mAb) targeting PHF-tau. BIIB076 can be used for passive immunity research in Alzheimer's disease (AD).
-
Lu AF87908
0 ImagesCat. No.: HY-P992400Lu AF87908 is an IgG1 monoclonal antibody targeting the p-Ser396/404 epitope of tau protein, which mainly binds to the pSer396 region. Lu AF87908 can be used in the research of Alzheimer's disease. The recommended isotype control is human IgG1 kappa (HY-P99001).
